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Effect of insulin therapy on renal hemodynamic response to
amino acids and renal hypertrophy in non-insulin-dependent
diabetes
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Division of Nephrology, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
Effect of insulin therapy on renal hemodynamic response to amino acids
and renal hypertrophy in non-insulin-dependent diabetes mellitus
(NIDDM). Since renal hemodynamic disturbances are important in
renal injury and are exacerbated by elevated plasma amino acid
concentrations in insulin-dependent diabetes, we measured glomerular
filtration rate (GFR) and renal plasma flow (RPF) after an overnight fast
and during amino acid infusion in 12 patients with NIDDM and nine
normal subjects. In the diabetic patients (plasma glucose 12.4 0.6
mmol/liter), the fasting GFR (113 6 vs. 98 7 ml/min 1.73 m2 in
normal subjects, P = 0.056) and RPF (635 37 vs. 540 20
ml/min 1.73 m2 in normal subjects, P < 0.05) were increased. After
amino acid infusion, the increase in GFR (159 7 vs. 121 6
ml/min 1.73 m2 in normal subjects, P < 0.05) and RPF (970 51 vs.
700 18 mllmin• 1.73 m2 in normal subjects, P < 0.05) were aug-
mented. Insulin infusion for 36 hours did not change these responses.
After three weeks of insulin therapy (plasma glucose 5.9 0.2 mmol/
liter), the amino acid-stimulated GFR (143 5 mI/mm 1.73 m2) and
RPF (836 30 ml/min 1.73 m2) declined (P <0.05), while the fasting
values remained unchanged. The right kidney volume was measured by
ultrasonography and found to decrease after three weeks of insulin
therapy from 188 12 to 165 9ml/l.73 m2 (P < 0.05). However, both
values were greater than that in the normal subjects, 124 13 mI/I .73
m2 (P < 0.01). Glomerular hyperfiltration and hyperperfusion became
augmented during hyperaminoacidemia in our NIDDM patients, Both
the augmented hemodynamic response to amino acids and renal hyper-
trophy regressed after three weeks of strict glycemic control.
Diabetic nephropathy in non-insulin-dependent diabetes mel-
titus (NIDDM) is becoming increasingly recognized as a com-
mon and devastating complication. Despite a lower overall
frequency of nephropathy in NIDDM (5 to 10%) compared to
insulin-dependent diabetes mellitus (IDDM) (30 to 50%), the
majority of patients in the Medicare End-Stage Renal Disease
program have NIDDM because it is much more common than
IDDM [1]. Moreover, in certain ethnic groups especially sus-
ceptible to NIDDM, such as Mexican Americans, Native Amer-
icans, and Blacks, the proportion of individuals who develop
renal disease approaches that in IDDM [2—4]. The reason(s) for
increased susceptibility to diabetic nephropathy in these ethnic
groups is not known, but a number of issues may be important:
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Younger age at onset of NIDDM; differences in dietary protein
and/or glycemic control; the frequency of hypertension (higher
in Blacks); or other genetic and environmental factors. Further-
more, in the White population, NIDDM generally develops
later in life when competing mortality from other processes,
such as coronary artery disease, may preclude the development
of nephropathy.
Despite the importance of the problem, little is known about
the pathophysiology of nephropathy in NIDDM. Glomerular
hyperfiltration, and in particular intraglomerular hypertension,
are pathogenic in IDDM-associated renal injury [5, 6]. We have
previously shown that amino acid-induced glomerular hyperfil-
tration may be a major mediator of the renal hemodynamic
disturbances in IDDM and that the susceptibility to these
perturbations is reduced by strict glycemic control [7]. Whether
similar renal hemodynamic responses occur in NIDDM has not
been resolved. This is an important issue because poor meta-
bolic control is associated with hyperphagia and excessive
protein consumption.
Glomerular hyperfiltration and hypertrophy are interrelated
phenomena and may interact to produce renal injury [8]. Renal
enlargement is a characteristic feature of IDDM which can be
attenuated by strict glycemic control [7, 91. Kidney size and its
response to an improved metabolic status have not been well-
evaluated in NIDDM.
We studied patients with NIDDM before and after strict
gtycemic control achieved by insulin infusion for 36 hours and
insulin therapy for three weeks. GFR and RPF were measured
after an overnight fast and during infusion of a balanced amino
acid solution. Kidney volume was determined by ultrasonogra-
phy before and after the three week period of strict glycemic
control.
Methods
Subjects
NJDDM. Twelve patients (8 women/4 men) with NIDDM
who were in poor metabolic control, despite therapy with oral
hypoglycemic agents and/or diet, were recruited from the
clinics associated with the University of Texas Health Science
Center at San Antonio, They had fasting plasma glucose mea-
surements between 10.0 and 17.0 mmollliter and hemoglobin
A1 values in excess of 7.5% (normal range 4 to 6%) on at least
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Table 1. Characteristics of patients wit h NIDDM at study entry
Age years 52.4 11.1
Diabetes duration years 7.2 3.2
Fasting plasma glucose mmol/liter 13.7 2.7
Hemoglobin A1 % 8.9 1.0
Blood pressure mm Hg 125 12/77 10
Retinopathy N:
present 8
absent 4
Diabetes treatment N:
oral agent 10
diet 2
Racial distribution N:
Mexican American 10
Black 1
Non-Hispanic White 1
All values are mean SD.
three consecutive occasions in the three months prior to study.
None of them had ever experienced ketoacidosis or became
diabetic before 35 years of age. The subjects had no evidence of
clinical renal disease as determined by blood pressure less than
140/90 mm Hg, negative urine dipstick tests for protein, and
plasma creatinine values less than 124 mmol/Iiter (1.4 mgldl) on
at least three consecutive occasions in the three months before
study. Subjects with background or early proliferative retinop-
athy were included, but those with advanced proliferative
retinopathy were excluded from the study. No subject mani-
fested clinical evidence of autonomic neuropathy. All subjects
had a stable body weight which was 149 27% of ideal body
weight (based upon the 1959 Metropolitan Life Insurance
tables) for at least three months prior to study. The subjects
were on no medication other than oral hypoglycemic agents.
Characteristics of the study group are shown in Table 1.
Normal controls. Nine normal subjects (2 women/7 men) who
were matched for age (56.4 4.2 years) and race to the NIDDM
group served as controls. They were all in good health and took
no medications. Their mean body weight was 120 19% of
ideal body weight.
Study protocol
All subjects were studied in the Frederic C. Bartter Clinical
Research Center (CRC) at the Audie L. Murphy Memorial
Veteran's Administration Hospital. Written, informed consent
was obtained from each participant prior to study entry. These
studies were approved by the Institutional Review Board of the
University of Texas Health Science Center at San Antonio.
NJDDM
The subjects were admitted to the CRC on the evening prior
to the first study day and maintained on their usual diabetes
treatment. On the following day (day 1), a 24-hour plasma
glucose profile was obtained with measurements made before
meals (07:00, 11:00, and 17:00 hours), two hours after meals
(09:00, 13:00, and 19:00 hours), at bedtime (23:00 hours), and at
03:00 hours. A 24-hour urine was collected for determination of
albumin, urea nitrogen and sodium. A blood sample for mea-
surement of hemoglobin A1 was also obtained. Body weight
was measured daily throughout the study.
The renal hemodynamic studies began at 07:00 hours after a
12-hour overnight fast on day 2. GFR and RPF were evaluated
by classic inulin and PAH clearance techniques. After intrave-
nous loading doses, inulin (Isotex, Friendswood, Texas, USA)
and PAH (Merck, Sharp, and Dohme, West Point, Pennsylva-
nia, USA) were given by continuous infusion. The subjectt
ingested an oral water load (10 mI/kg) at the initiation of the
infusion. Urine and plasma for determination of inulin and PAH
were collected every 30 minutes after a one-hour equilibratior
period. Urine output was quantitatively replaced with oral
water to maintain a urine flow rate of 7 to 10 mllmin. Only
studies where the urine flow rate remained stable within thit
range were accepted. Stability of the urine flow rate wat
assumed to reflect effective bladder emptying. After a two-how
baseline period, a balanced amino acid solution (Travasol 10%,
Travenol Laboratories, Deerfield, Illinois, USA) was infused
for three hours. The amino acid composition (mmol/liter) of this
solution was: Leucine 55.6, isoleucine 45.7, lysine 39.7, valine
49.5, phenylalaninc 33.9, histidine 30.9, threonine 35.3, methi-
onine 26.8, tryptophan 8.8, alanine 232.3, arginine 66.0, glycine
137.2, proline 59.1, serine 47.6, and tyrosine 2.2. The infusior
rate was 0.043 mI/kg- mm based on ideal body weight. We have
previously found that this dose increases the plasma aminc
acids to concentrations that are two to three times greater thar
those at baseline [71. Ideal body weight was chosen for the dose
determination because most of the amino acids flux into skeletal
muscle and liver [10]. Thus, in subjects with excess body fai
(such as those in our study), dosing the amino acids based or
ideal body weight is more likely to produce consistent hyper-
aminoacidemia. Plasma glucose was measured every 15 min-
utes. No insulin was infused and the plasma glucose remainec
at the fasting level (12.4 0.06 mmol/liter) throughout the
study. Blood pressure was determined at 30-minute intervab
for the six-hour study period.
After the clearance study was completed, an intravenout
insulin infusion was started at 18:00 hours with the rate adjustec
to achieve fasting and pre-meal glucose values  7.5 mmol/lite
and two-hour post-prandial values 10 mmol/liter. The insulir
infusion was continued throughout day 3 for a total duration ol
approximately 36 hours. A 24-hour plasma glucose profile and
urine collection were obtained on day 3. The renal hemody.
namic studies were repeated on day 4 exactly as on day 2
except that the plasma glucose was clamped at the fastinl
euglycemic level (5.9 0.2 mmollliter) by means of a variable
insulin infusion which ranged from 0.20 to 0.30 mU/kg mir
during the baseline period to 0.30 to 0.50 mU/kg - mm durinl
the amino acid infusion.
The subjects were discharged on insulin regimens consistin
of NPH and regular insulin given twice daily. All subject5
performed home glucose monitoring with a blood glucose metei
four to six times daily. Insulin doses were adjusted in response
to these measurements in order to accomplish the same goals a
those achieved during the insulin infusion. The mean total dail)
dose of insulin in the group was 54 7 units. The patients were
instructed to eat a weight-maintaining diet with a caloric distri
bution of 55% carbohydrate, 25% fat, and 20% protein. B
dietary history, the protein intake of the diabetic patient
ranged from ito 1.5 g!kg day; they were counseled to maintair
this level of protein consumption throughout the study.
After three weeks of insulin therapy, the subjects returned tc
the CRC for additional studies. Their insulin regimens were
continued, and on day 1 a 24-hour glucose profile and urine
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collection were obtained. Blood also was collected for measure-
ment of hemoglobin A1 and the subjects were weighed. The
renal hemodynamic studies were repeated on day 2 with the
plasma glucose clamped at the fasting euglycemic level (5.9
0.2 mmol/liter) by means of a variable insulin infusion which
ranged from 0.20 to 0.30 mU/kg mm during the baseline period
to 0.30 to 0.50 mU/kg mm during the amino acid infusion.
Normal controls
The subjects were admitted to the CRC at 06:30 hours after a
12-hour overnight fast. The renal hemodynamic studies were
performed exactly as described for the diabetic patients except
that no insulin was infused.
Kidney volume measurements
Kidney volume was determined on day I of each admission in
the NIDDM patients and on the same day as the renal hemo-
dynamic studies in the normal subjects. The measurements
were made by ultrasonography and kidney volume was calcu-
lated by a method we have described previously [7]. The mean
coefficient of variation on duplicate determinations was 6%.
Only the right kidney volume was assessed due to technical
difficulties associated with imaging the left kidney in obese
individuals. Technically acceptable studies were available in
10/12 (85%) diabetic patients and 7/9 (78%) normal subjects.
There was no direct correlation between the degree of obesity
and inability to adequately image the kidney. The difficulty was
more related to the distribution of body fat in an individual
subject. Kidney volume was expressed as mLIl.73 m2 using
idealized body surface area.
Analytical methods
Plasma glucose was measured by the glucose oxidase tech-
nique using a Beckman II Glucose Analyzer (Beckman Instru-
ments, Fullerton, California, USA). Urinary urea nitrogen was
determined by a SMAll autoanalyzer (Technicon Corporation,
Tarrytown, New York, USA). Urinary sodium was analyzed by
Ilame photometry (Model Klina, Beckman). Hemoglobin A1
was measured by the Bio-Rad Hemoglobin A1 Column Test
Method (Bio-Rad Laboratories, Hercules, California, USA).
Enulin and PAH in plasma and urine were analyzed by standard
colorimetric assays [11, 12]. Urinary albumin was determined
by radioimmunoassay using a commercially available kit (Diag-
nostic Products Corporation, Los Angeles, California, USA).
Data analysis
Inulin and PAH clearances were calculated by standard
lormulas and expressed as ml/min 1.73 m2, using idealized
body surface area. Basal GFR and RPF refer to the average of
the baseline values and amino acid-stimulated GFR and RPF
represent the mean of measurements obtained during the last
lour of amino acid infusion. Dietary protein intake was esti-
mated based upon 24-hour urinary urea nitrogen excretion as
rollows: Protein intake = (urinary urea nitrogen + non-urea
nitrogen) x 6.25. Non-urea nitrogen is taken to be 0.031 g
NVkg d, assuming nitrogen balance [13].
The analysis of variance (ANOVA) with repeated measures
was used to compare data obtained from the three sequential
studies in the diabetic patients and to assess changes in the
arameters measured over the time course of a given experi-
ment. Comparisons between the diabetic patients and the
normal subjects were made by the unpaired (-test. The paired
t-test was used to assess responses before and after three weeks
of insulin therapy in the diabetic patients. All data are ex-
pressed as mean SE. Statistical significance was defined as P
<0.05.
Results
Glycemic control
The fasting and mean 24-hour plasma glucose concentrations
in the diabetic patients were 13.6 0.8 and 14.6 0.6
mmol/liter, respectively, before insulin therapy (Fig. 1). After
36 hours and three weeks of insulin therapy, their mean fasting
plasma glucose concentrations were 6.4 0.3 and 6.8 0.6
mmol/liter, while the 24-hour mean values were 8.1 0.3 and
7.7 0.2 mmolfliter, respectively. The mean glycosylated
hemoglobin concentration declined from 8.9 0.3 to 6.9 0.3
percent (P < 0.001) after three weeks of insulin therapy.
The plasma glucose concentrations during the renal hemody-
namic studies were consistent with the ambient levels of
glycemia. Before insulin therapy, the plasma glucose values
during the baseline study and during the amino acid infusion
were 12.6 0.6 and 12.2 0.6 mmollliter, respectively. After
36 hours and three weeks of insulin therapy, the plasma glucose
levels during the baseline studies were 5.7 0.2 and 5.8 0.2
mmol/liter, and the values during the amino acid infusions were
6.1 0.2 and 5.9 0.1 mmol/liter, respectively.
Dietary protein and sodium intakes
The estimated protein intake in the diabetic patients remained
within the prescribed range throughout the study; it was 1.35
0.09 g/kg day before insulin therapy, 1.30 0.10 g/kg day
during the 36-hour insulin infusion, and 1.34 0.06 g/kg day
after three weeks of insulin therapy. The 24-hour urinary
sodium excretion was 175 17 mmol/day before insulin ther-
apy, 130 12 mmol/day during the 36-hour insulin infusion, and
184 14 mmol/day after three weeks of insulin therapy (P not
significant). The mean body weight in the diabetic patients was
83.0 4.6 kg before insulin therapy, and after 36 hours and
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Fig. 1. Twenty-four hour mean (± SE) plasma glucose profiles in 12
patients with NIDDM before insulin therapy (i), after 36 hours of
insulin infusion (O) and after three weeks of insulin therapy ().
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three weeks of insulin therapy, the respective values were 83.2
4.6 kg and 83.4 4.4 kg (P not significant).
Renal hemodynamic studies
Under basal conditions (that is, after the overnight fast), the
GFR in the diabetic patients did not change between the study
periods; it was 113 6 ml/min 1.73 m2 before insulin therapy,
113 5 mllmin' 1.73 m2 after the 36-hour insulin infusion, and
115 4 mI/mm 1.73 m2 after three weeks of insulin therapy
(Fig. 2). These values were numerically greater than the basal
GFR in the normal subjects, 98 7 ml/min 1.73 m2, but the
differences just missed statistical significance (P = 0.056, P =
0.056, P = 0.050, respectively). The GFR in the amino acid-
stimulated state was greater in the diabetic patients before
insulin therapy, 159 7 mI/mm 1.73 m2, and after the 36-hour
insulin infusion, 158 6 mi/mm 1.73 m2, than after three
weeks of insulin therapy, 143 5 ml/min 1.73 m2 (P < 0.05).
All of these values were greater than that in the normal
subjects, 121 6 mI/mm 1.73 m2 (P < 0.05). However, the
percent rise in GFR declined in the diabetic patients from 43
7% before insulin treatment and 40 4% after the 36-hour
insulin infusion, to 24 2% (P < 0.05) after three weeks of
insulin therapy. The latter value was similar to that observed in
the normal subjects, 26 5%.
The pattern for RPF throughout the studies paralleled that of
GFR. The basal RPF in the diabetic patients was 635 37
ml!min 1.73 m2 before insulin treatment, 626 32 ml!
min 1.73 m2 after the 36-hour insulin infusion, and 641 24
ml!min 1.73 m2 after three weeks of insulin therapy (Fig. 3).
All of these values exceeded the basal RPF in the normal
subjects, 540 20 ml!min 1.73 m2 (P < 0.05). During the
amino acid infusion, the RPF in the diabetic patients rose to 970
51 mllmin 1.73 m2 before insulin treatment and 911 45
ml/min 1.73 m2 after the 36-hour insulin infusion. The amino
acid-stimulated RPF fell to 836 30 ml/min 1.73 m2 (P < 0.05)
after three weeks of insulin therapy. These values were greater
than that in the normal subjects, 700 18 ml/min 1.73 m2 (P <
0.05). However, the percent increase in the RPF in the diabetic
patients dropped from 53 4% before insulin treatment and 46
5% after the 36-hour insulin infusion, to 32 5% (P < 0.05)
after three weeks of insulin therapy. The last measurement was
not significantly different from that in the normal subjects, 29
3%.
To determine if differences in body weight between the
control subjects and the diabetic patients influenced the results,
a subgroup analysis including only control subjects and diabetic
patients who could be individually matched to within 7% of
ideal body weight was performed. The ideal body weight of
these control subjects (N 6) was 132 19% and that of the
diabetic patients (N = 6) was 134 17%. The values for GFR
and RPF under the various study conditions were similar to
those of the groups as a whole.
Kidney volume
The right kidney volume in the patients with NIDDM was
enlarged, 188 12 ml!1.73 m2, compared to that observed in the
normal subjects, 124 13 ml/l.73 m2 (P < 0.01) (Fig. 4). After
three weeks of insulin therapy, the mean kidney size in the
diabetic patients decreased, 165 9 ml/l.73 m2 (P < 0.05), but
it remained significantly larger than the mean normal value (P <
0.01).
Urinary albumin excretion
Microalbuminuria (defined as a rate of urinary albumin ex-
cretion  20 g/min) was present before insulin treatment in
three of 12 patients with NIDDM (Fig. 5). In two of these
patients, the urinary albumin excretion rate declined into the
normal range after 36 hours of insulin infusion and remained
there after three weeks of therapy. There was also a trend for
the urinary albumin excretion rate to fall in those without
microalbuminuria. No study parameter differed between the
diabetic patients with or without microalbuminuria.
Discussion
The patients with NIDDM in this study exhibited glomerular
hyperfiltration of borderline significance and modest renal hy-
perperfusion in the fasting state. However, these hemodynamic
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Fig. 2. Mean (± SE) GFR in nine normal
subjects and 12 patients with NIDDM before
insulin therapy, after 36 hours of insulin
infusion, and after three weeks of insulin
therapy. A illustrates absolute values for GFR
in the basal state (E') and during amino acid
infusion (Q). B represents the amino acid-
stimulated percent rise in GFR over the
baseline values. * P value <0.05 for diabetic
patients compared with normal subjects. t P
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Fig. 3. Mean (± SE) RPF in nine normal
subjects and 12 patients with NIDDM before
insulin therapy, after 36 hours of insulin
infusion, and after three weeks of insulin
therapy. A illustrates absolute values for RPF
in the basal state (La) and during amino acid
infusion (El). B represents the amino acid-
stimulated percent rise in RPF over the
baseline values. * p value < 0.05 for diabetic
patients compared with normal subjects. t P
value < 0.05 for diabetic patients after three
weeks of insulin therapy compared with the
measurements before insulin treatment and
after 36 hours of insulin infusion.
changes became greatly augmented when plasma amino acid
concentrations were physiologically elevated. The increased
responsiveness to hyperaminoacidemia was similar to that
observed in IDDM [7]. Thus, fasting measurements of kidney
function may underestimate the true degree of glomerular
hyperfiltration and meals containing protein are likely to exac-
erbate the hemodynamic disturbances in both types of diabetes.
Indeed, Kupin et a! found that the fasting GFR increased from
113 to 143 mi/mm 1.73 m2 when dietary protein was raised
from 1.5 to 3.5 glkg din conventionally-treated IDDM patients
[14]. Moreover, the actual increase in renal hemodynamics was
probably greater because the measurements did not take into
account the acute effects of meals. Our data provide a sound
physiologic rationale for avoidance of excess dietary protein, or
Before Insulin Insulin
insulin infusion (36 hrs) Rx (3 weeks)
Fig. 5. Urinary albumin execution rate in 12 patients with NIDDA
before insulin treatment, after 36 hours of insulin infusion, and afte
three weeks of insulin therapy.
possibly protein restriction, because of the importance ol
hemodynamic perturbations in diabetes-associated renal injury.
There has been little data published previously on rena
function prior to the onset of nephropathy in patients witF
NIDDM. Some European authors have reported that rena
function is not altered [15, 16]. However, Palmisano et a! founc
that approximately 40% of patients with recent onset NIDDM
in Brooklyn, New York have glomerular hyperfiltration anc
Myers, et al reported that the mean GFR was increased by 159
in Pima Indians with NIDDM for less than three years [17, 181.
The discordant results may be related to differences in study
populations and conditions. Our patients were predominantly
Mexican American; those in the study of Palmisano et al were
Black, and Myers et a! studied Native Americans. These ethnic
groups are known to be especially susceptible to NIDDM and
have a greater frequency of diabetic nephropathy than White
patients with NIDDM [2, 3, 41. It is plausible to suggest that the
patients who are more susceptible to diabetic nephropathy may
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Fig. 4. Right kidney volume in seven normal subjects and ten patients
with NIDDM before and after three weeks of insulin therapy. ()
represent the mean (± SE) values in the three groups. ** P value < 0.01for normal subjects compared to diabetic patients before and after
insulin treatment. * Pvalue <0.05 for the comparison before and after
three weeks of insulin therapy in the diabetic patients.
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also be predisposed to antecedent hemodynamic disturbances.
Additionally, differences in metabolic control or dietary protein
intake, and whether or not the patients were studied in the
fasting state, may account for the inconsistent results. Even
less has been published about the acute renal response to a
protein load in NIDDM. Bosch et a! noted a blunted response to
a protein meal, but their NIDDM patients had overt nephrop-
athy which may have attenuated the renal vasodilatory and
hyperfiltration response [19].
The mechanisms responsible for amino acid-induced glomer-
ular hyperfiltration have not been clarified, but amino acids
have been shown to act directly on the kidney [203 and through
a number of potential mediators. Glucagon is released when
plasma amino acid concentrations are increased and it can raise
the GFR. Parving et al reported that the renal response to
glucagon infusion in diabetic patients was nearly twice as great
as that in normal subjects [21]. Slomowitz et a! found that the
renal hemodynamic response to arginine became greatly exag-
gerated after captopril treatment in diabetic patients [223. Thus,
the diabetic kidney may be especially sensitive to vasodilating
factors such as glucagon, bradykinin, or prostaglandins, and to
inhibition of vasocostricting influences such as angiotensin II.
Recent data from King and co-workers indicate that endothe-
hal-derived relaxing factor (EDRF), which is generated by the
metabolism of arginine to nitric oxide, also contributes to amino
acid-induced renal hyperperfusion and hyperfiltration [23]. Al-
though such studies have not yet been done in diabetes, it is
possible that altered EDRF synthesis, metabolism or sensitivity
may be involved in the augmented renal hemodynamic response
to amino acids.
Strict glycemic control normalized the increased renal re-
sponsiveness to amino acids. Although this was evident after
three weeks of insulin therapy, 36 hours of insulin infusion did
not alter renal function. The minimal time necessary for this
process to occur cannot be deduced from the present data, but
a similar time course was noted in our IDDM patients [7].
Nevertheless, normalization of the augmented renal hemody-
namic response to amino acids required sustained improvement
in metabolic control. This suggests that the hemodynamic
changes may not be purely functional and could be related to
alterations in kidney structure. It is noteworthy that renal
hypertrophy regressed in most of our NIDDM patients over the
same period of time. An enlarged filtration surface or altered
tubuloglomerular feedback due to tubular hypertrophy could be
permissive for an augmented renal vasodilatory and hyperfiltra-
tion response.
The changes in renal hemodynamics and kidney size after
strict glycemic control in patients with NIDDM were direction-
ally similar to those we observed in patients with IDDM [7].
However, there were some differences between the two groups
which should be noted. First, RPF was increased above control
values and GFR tended to be elevated (borderline significant) in
the fasting state in the NIDDM patients. In contrast, fasting
renal hemodynamics in the IDDM patients did not differ from
their control values. Second, kidney size was enlarged more in
the NIDDM group than in the IDDM group relative to their
respective control values. GFR has been found to roughly
correlate with kidney size [24]. Although kidney size is not the
sole determinant of function, it is possible that a certain degree
r.frnI hinertrnnhv i' ngcpccnrv for hacal hvnernerfusion and
hyperfiltration to occur. A third important difference was that
strict glycemic control completely corrected both the renal
hemodynamic abnormalities and renal hypertrophy in IDDM,
whereas they were only attenuated in NIDDM. Several differ-
ences between the NIDDM and IDDM patients may account for
these discrepancies. Since it is more difficult to date the onset of
NIDDM than IDDM, the NIDDM patients could have had a
substantially longer duration of diabetes. The NIDDM group
was also more severely hyperglycemic than the IDDM group
based on fasting and 24-hour plasma glucose profiles. More-
over, strict glycemic control in the NIDDM patients did not
improve the metabolic status as much as it did in the IDDM
patients. Greater hyperinsuhinemia associated with insulin re-
sistance in NIDDM could lead to greater renal growth [81.
Finally, the older age of our NIDDM patients could result in
less tissue plasticity and a smaller reduction in kidney size after
strict glycemic control.
In summary, renal hemodynamic disturbances and renal
hypertrophy were present in a group of predominantly Mexican
American patients with NIDDM and were greater than those we
previously reported in patients with IDDM [7]. Hyperaminoac-
idemia in both types of diabetic patients led to augmented
glomerular hyperfiltration and hyperperfusion. This suggests
that the diabetic kidney may be especially susceptible to
hemodynamic injury when dietary protein is increased. Thus,
avoidance of a high protein intake, even before the onset of
diabetic nephropathy, is likely to be prudent. Most importantly,
we found that strict glycemic control normalized the augmented
renal hemodynamic response to amino acids and attenuated
renal hypertrophy. Based upon our current understanding of
mechanisms of renal injury, good blood glucose control should
be protective against renal disease in NIDDM.
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